Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc11.3 | Rapid Communications 11: Thyroid 2 | ECE2022

Is the pre-conceptional TSH optimization useful in women submitted to assisted reproduction technology?

Maria Vannucchi Guia , Campi Irene , Cagnina Serena , Covelli Danila , Persani Luca , Mignini Renzini Mario , Fugazzola Laura

Background: thyroid function (TSH levels) and thyroid autoimmunity are involved in the immunomodulation of early pregnancy stages and can affect assisted reproductive technology (ART).Aims: 1) to evaluate if pre-conceptional TSH is associated with an increased risk of miscarriage, 2) to identify a TSH cut-off significantly associated with risk of miscarriage, 3) to assess the impact of TSH levels on primary and surrogate outcomes.M...

ea0084ps3-13-118 | Pregnancy & Iodine | ETA2022

Which is the best pre-conceptional TSH cut-off in women submitted to assisted reproductive technology?

Vannucchi Guia , Campi Irene , Cagnina Serena , Covelli Danila , Mignini Renzini Mario , Persani Luca , Fugazzola Laura

TSH is involved in the immunomodulation of early pregnancy stages. Thyroid guidelines have indicated 2.5 mU/l as the best TSH level below which women undergoing assisted reproductive technology (ART) need to be maintained, though this treshold is still controversial. Aims of the present study were to evaluate if pre-conceptional TSH is associated with an increased risk of miscarriage, to identify a TSH cut-off significantly associated with risk of miscarriage and to assess the...

ea0022p816 | Thyroid | ECE2010

A single small dose of rituximab may be effective in Graves' orbitopathy

Covelli Danila , Vannucchi Guia , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

The anti-CD 20 antibody rituximab (RTX) has been employed in the treatment of several autoimmune diseases and its effect may not involve autoantibody secretion. Preliminary studies have shown that RTX induced improvement of active Graves’ orbitopathy (GO) but caused no change of serum anti-thyroid antibodies in relation to peripheral CD 20+ cells depletion, usually observed at the second week after therapy. A 50-year-old woman with GO predominantly active in the left eye ...

ea0020p120 | Thyroid | ECE2009

Seasonal occurrence of Graves’ disease and associated orbitopathy at diagnosis

Campi Irene , Vannucchi Guia , Covelli Danila , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

A seasonal occurrence of Graves’ disease (GD) has been reported in previous studies, with a peak of frequency in the warmer half of the year (Ford 1988, 1991, Westphal 1994) or the period of the year with a higher iodine intake (Phillips 1985); other studies (Facciani 2000) have failed to find a different seasonal occurrence of Graves’ orbitopathy (GO). Aim of the present study was to evaluate a possible seasonal difference in the onset of GD and GO in a series of ou...

ea0063gp81 | Thyroid Autoimmune Disorders | ECE2019

Retrospective analysis of the efficacy of three different dose regimens of rituximab in patients with active moderate-severe graves’ orbitopathy

Lazzaroni Elisa , Covelli Danila , Campi Irene , Vannucchi Guia , Curro Nicola , Pirola Giacinta , Guastella Claudio , Dolci Alessia , Arosio Maura , Salvi Mario

Aim: The aim of this retrospective study was to assess the efficacy of different doses of rituximab (RTX) in patients with active moderate-severe Graves’ Orbitopathy (GO).Methods: Overall 40 patients, 5 M/35 F; mean age (± S.D.) 58±11 years were treated with RTX; 21 were smokers. The patients received the following treatment: 14 patients (group 1) a single 100 mg dose; 15 patients (group 2) a single 500 mg dose and 11 Patien...

ea0037gp.27.05 | Thyroid – hyperthyroidism and treatment | ECE2015

Effect of a very low dose of rituximab on active moderate–severe Graves' orbitopathy: an interim report

Vannucchi Guia , Campi Irene , Covelli Danila , Curro Nicola , Dazzi Davide , Avignone Sabrina , Sina Clara , Guastella Claudio , Pignataro Lorenzo , Salvi Mario

Previous studies have shown that Rituximab (RTX) is effective as a disease modifying drug at doses of 500 mg or 1000×2 mg in active Graves’ orbitopathy (GO). We have conducted a pilot study (EUDRACT 2012-001980-53) in which patients with active moderate-severe GO were treated with a single infusion of low dose RTX (100 mg). Ten patients were enrolled of whom seven completed the study at 52 weeks. Five patients did not respond to a previous treatment with i.v. methylp...

ea0016p810 | Thyroid | ECE2008

Effects of rituximab (RTX) treatment on IL-6 and soluble IL-6 receptor secretion in patients with thyroid-associated ophthalmopathy (TAO)

Campi Irene , Vannucchi Guia , Dazzi Davide , Covelli Danila , Bonara Paola , Curro Nicola , Beck-Peccoz Paolo , Salvi Mario

We described a significant clinical response to RTX treatment in patients with active TAO. In order to understand the possible mechanisms of action of RTX, we measured serum concentrations of IL-6 and its soluble receptor (sIL-6R). We treated 10 patients with RTX: 8 women, 2 men aged 31–51 yr with Graves’ disease. We also treated 14 patients with i.v. steroids (IVGC). All had active TAO. In all patients we studied thyroid function, serum autoantibodies and peripheral...

ea0063gp71 | Thyroid Autoimmune Disorders | ECE2019

The randomised probiotic trial of indigo study (investigation of novel biomarkers and definition of role of the microbiome in Graves’ orbitopathy)

Salvi Mario , Colucci Giuseppe , Masetti Giulia , Covelli Danila , Muller Ilaria , Koehling Hedda , Garaiova Iveta , Michael Daryn , Zhang Lei , Ludgate Marian , Marchesi Julian , Biscarini Filippo

Background: Changes of the gut microbiota may impact on the mechanisms of immune tolerance in Graves’ disease (GD) and Graves’ orbitopathy (GO). Probiotics, which contain live micro-organisms, can modify the composition of the gut microbiota.Aims: We tested in a double-blind randomized placebo controlled trial whether the administration of a well-characterized, commercially available, probiotic would 1) modify the microbiota composition in GD/G...

ea0049ep1342 | Thyroid (non-cancer) | ECE2017

Immune reaction to food antigens in Graves’disease (GD) patients: role of gliadin and other food antigens

Covelli Danila , Colucci Giuseppe , Salvi Mario , Kaiser Ulrike , Eckstein Anja , Burlacu Maria Cristina , Daumerie Chantal , Richell Gez , Perros Petros , Draman Mohd Shazli , Ludgate Marian , Masetti Giulia , Biscarini Filippo

As known, an imbalance of the gut microbiota is associated with a higher risk for autoimmune diseases. Moreover the increased rates of autoimmunity reported in urban residential areas worldwide suggest a possible influence of diet. We report on the antibody response to food antigens in GD patients. Since 10% of celiac patients develop an autoimmune thyreopathy we focused on gliadin (DGP), transglutaminases (tTG) and 40 other food antigens (FA). Commercially available ELISA ass...

ea0037gp.07.01 | Reproduction: Female and other | ECE2015

Preconceptional TSH and miscarriage in infertile women submitted to IVF

Vannucchi Guia , Covelli Danila , Renzini Mario , Brigante Claudio , Coticchio Giovanni , Canto Maria Beatrice Dal , Fadini Rubens , Dazzi Davide , Negro Roberto , Fugazzola Laura

It is known that high levels of TSH are associated with higher miscarriage risk, though the precise TSH cut-offs are debated. Aim of the present study was to evaluate if pre-conceptional TSH levels associate with increased risk of early miscarriage in a large series of infertile women submitted to IVF and to determine the threshold of TSH associated with the highest prevalence of pregnancy loss. We retrospectively studied 1484 infertile women (mean±age 36.7±4.1 years...